On Feb. 22, Ministry of Education Science And Technology Development Center officially issued the project of Science and Technology Progress Award in 2016 College Scientific Research Excellent Achievements. The project of “Study on key problems in prophylaxis and treatment of helicobacter pylori infection and the clinical application” won the Second Prize of Science and Technology Progress Award (Promotion Award) in 2016 College Scientific Research Excellent Achievements.
This project was mainly completed by Nanchang University. The members of the winning team included Lv Nonghua, Xie Yong, Shu Xu, Zhu Meng, Xie Chuan, Yang Zhen, Gong Yangong, Hong Jungong, Liu Dongsheng, Zhu Zhenhua, Huang Deqiang, Zhou Xiaojiang, Wang Jian, Guo Guihai, Wang Chongwen. The helicobacter pylori team lead by Lv Nonghua and Xie Yong has been long engaged in the study on key problems in prophylaxis and treatment of helicobacter pylori infection and the clinical application. Under the support of improved scientific research platform, the team has been carrying a serial study for as long as 16 years by relying on platforms such as department of gastroenterology, Jiangxi Province Digestive Diseases Institute, and Jiangxi Province Digestive Diseases Key Laboratory and by being funded by National Major Special Project, Science and Technology Support Plan and National Funded Project.
The project team has carried out an epidemiological survey on Hp resistance, and acquired the epidemiologic materials of Hp resistance with the widest coverage at present in China. They mainly completed the RCT study on the furazolidone bismuth reagent quadruple regimen with the largest sample size currently all over the world and involving most sites.
The results validates that, this regimen is characterized by a high eradication rate, a low resistance rate, safety, inexpensiveness, and the capability of effectively overcoming the current Hp resistance; it is especially applicable to China and developing countries for promotion and application due to its huge social benefits and economic benefits. An anti-Hp traditional Chinese medicine was developed through automatic innovation and the result transformation was completed. The “drug clinical trial approval” for class VI traditional Chinese medicine, “Puding Hewei Capsules” with “Heat-Relieving and Anti-inflammatory Regimen” as the component was acquired, and it becomes the first class VI traditional Chinese medicine in China which is developed according to the drug anti-Hp effects, result conversion and approval acquisition. A serial study has been carried out on the mechanism of early carcinogenesis of Hp infection from the multiple perspectives, providing new ideas for the study for the relationship between the host - Hp interaction and the gastric carcinogenesis. The Hp immunopathogenesis and vaccine immunoprotection mechanism have been studied from a new angle. The project results have greatly contributed to the progress and development of Chinese prophylaxis and treatment of Hp treatment and they also facilitate the inclusion of this discipline into a national key discipline constructed in the “211” project, into the first batch of key clinical specialties, and into the prioritized disciplines among Jiangxi Province colleges.
As is reported, there were 312 awards in 2016 College Scientific Research Excellent Achievements Evaluation, 9 of which fell into the category of Science and Technology Progress Award (Promotion Award), and Jiangxi’s colleges won 2.
